| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
DL-2-Aminohexanoic acid-d9 has no pharmacological target. Its parent compound, norleucine, is a non-proteinogenic amino acid that can interfere with amino acid transport and protein synthesis. The deuterated standard is used analytically to quantify norleucine enantiomers and to study D-amino acid metabolism.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
In vitro, DL-2-aminohexanoic acid-d9 is used as an internal standard for chiral LC-MS/MS quantification of norleucine. Norleucine itself has been used as a methionine analog and can be incorporated into proteins, but its specific pharmacological activity is not well characterized. |
| ln Vivo |
No in vivo efficacy or toxicity data exist for DL-2-aminohexanoic acid-d9. It may be used as a tracer to study amino acid absorption and metabolism. The deuterated standard is used analytically to support these studies.
|
| Enzyme Assay |
For chiral LC-MS/MS quantification, DL-2-aminohexanoic acid-d9 is added to plasma or tissue homogenate before extraction. Samples are derivatized with a chiral reagent (e.g., Marfey’s reagent) and analyzed by reverse-phase LC-MS/MS. The norleucine-to-d9-internal-standard ratio is used for quantification.
|
| Cell Assay |
For cell-based studies, cells are incubated with norleucine or norleucine-d9, and incorporation into proteins is quantified by LC-MS/MS after hydrolysis. The deuterated standard is used for quantification of norleucine in the medium and cell extracts.
|
| Animal Protocol |
For in vivo tracer studies, norleucine-d9 is administered to rodents, and plasma and tissue samples are collected at serial time points. Norleucine and its metabolites are quantified by chiral LC-MS/MS. Tissue distribution and incorporation into proteins are assessed.
|
| References |
| Molecular Formula |
C6H4D9NO2
|
|---|---|
| Molecular Weight |
140.23
|
| Exact Mass |
140.151
|
| CAS # |
2243004-88-6
|
| Related CAS # |
H-DL-Nle-OH;616-06-8
|
| PubChem CID |
163322667
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
-1.5
|
| tPSA |
63.3
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
9
|
| Complexity |
93.1
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[2H]C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C(C(=O)O)N
|
| InChi Key |
LRQKBLKVPFOOQJ-YNSOAAEFSA-N
|
| InChi Code |
InChI=1S/C6H13NO2/c1-2-3-4-5(7)6(8)9/h5H,2-4,7H2,1H3,(H,8,9)/i1D3,2D2,3D2,4D2
|
| Chemical Name |
2-amino-3,3,4,4,5,5,6,6,6-nonadeuteriohexanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.1311 mL | 35.6557 mL | 71.3114 mL | |
| 5 mM | 1.4262 mL | 7.1311 mL | 14.2623 mL | |
| 10 mM | 0.7131 mL | 3.5656 mL | 7.1311 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.